Outcome of neoadjuvant-treated young patients with hormone receptor-positive breast cancer.

e11577 Background: Although late-stage at diagnosis and aggressive histologic subtypes partially explain the poor prognosis in young women with breast cancer (BC), other biological differences may dictate patients’ outcomes. The purpose of our study was to compare the recurrence-free survival (RFS) among neoadjuvant-treated patients according to age and histologic subtypes. Methods: All consecutive patients with BC diagnosed at the National Cancer Institute in Mexico between 2007-2013 were included. BC was classified as Hormone-receptor (HR)+ and HER2-, HER2+ and triple-negative (TN). The Chi-square test was used for comparison between groups according to age, [≤40 (young) vs. >40] and the association of clinical and histologic factors with RFS was assessed with Cox proportional hazard analysis. Results: Of the 3,110 included patients, 40% received neoadjuvant treatment and 18% were young. For neoadjuvant-treated patients there was no distribution difference in histologic subtypes between age groups. Alth...